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Abstract 
Background: Cow’s milk allergy (CMA) is the most common allergic disease in infancy. It is not clear, whether infants 
with CMA have an increased risk of developing other allergic diseases later in life, the so-called “allergic march”. We 
aimed to detect genetic associations of CMA using reported single nucleotide polymorphisms (SNP) in other allergic 
diseases and genetic mutations within the filaggrin (FLG) gene. Both to investigate possible causes of CMA, which also 
suggests an “allergic march”.
Methods: Thirty children from the Dutch EuroPrevall birth cohort study with CMA in infancy and twenty-three 
healthy controls were studied. Six candidate SNPs were selected (minor allele frequency 10–50 % combined with a 
large effect) based on the literature. Thirteen FLG candidate mutations were selected spread over repeats 1, 3, 4, 5, 6, 7, 
9 and 10 respectively.
Results: We found two SNP’s, rs17616434 (P = 0.002) and rs2069772 (P = 0.038), significantly associated with CMA. 
One is located near the toll like receptor 6 (TLR6) gene, which functionally interacts with toll-like receptor 2, and is 
associated with an increased risk of other allergic diseases. One is located at the Interleukin 2 (IL2) locus. Twelve FLG 
amplicons were analyzed, but showed no significant enrichment. Nevertheless, we did observe more FLG mutations 
in the CMA-group compared to controls.
Conclusion: We significantly associated two SNPs with CMA, suggesting that variation in the TLR6 and IL2 genes con-
tribute to the expression of CMA. In addition, since TLR6 and IL2 were earlier associated with other later onset allergies, 
this also favours the “allergic march” hypothesis. We observed more FLG mutations in the CMA-group, albeit we found 
no statistical significant enrichment of FLG mutations. Further studies are necessary to investigate the role of common 
variants and FLG or other skin barrier gene mutations in CMA.
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Background
Cow’s milk allergy
Cow’s milk allergy (CMA) is the most common food 
allergy in young children, although an accurate incidence 
is difficult to establish because of discrepancies between 
self-reported and proper diagnosed allergy [1–4]. CMA 
and other food allergies have a heterogeneous clinical 
presentation, the estimated heritability of food-specific 
IgE ranged from 0.15 (cow’s milk) to 0.35 (wheat) [5, 6]. 
Young children are likely to develop tolerance for cow’s 
milk protein within a few years. However, infants who 
suffered from CMA in their early childhood seem to have 
an increased risk to develop other allergic diseases like 
asthma later in life [6–12]. Accumulating evidence sug-
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immune-system and epicutaneous allergen sensitization 
[6, 13, 14]. Pre- and postnatal environmental factors, par-
ent-of-origin factor and stress are likely to be involved in 
the susceptibility and expression of allergy [15]. So far, a 
clear cause for CMA has not been found.
Genetic component of food allergy
Genetic surveys on food allergy (FA) are to our knowl-
edge still limited to candidate gene studies, and studies 
investigating CMA solely are not available. GWAS on 
other atopic diseases like asthma and eczema identified 
few candidate genes, as presented by Bonnelykke et  al. 
However, these genes were only found in single FA allergy 
studies, as presented by Tan et  al. [16–18]. Recently, it 
was shown that loss-of-function mutations of filaggrin 
(FLG) are a major risk factor for peanut food allergy [19]. 
FLG has already been described in studies on eczema [16, 
20]. The FLG protein is an important skin barrier protein, 
but is not expressed in the gastrointestinal tract [13, 19]. 
Studies on the sensitizing mechanisms involved in FA, 
suggest that exposure to food antigens through the skin, 
i.e. epicutaneous, leads to allergic sensitization while 
(early) oral administration of food antigens just may pre-
vent the onset of allergy [13]. An impaired skin barrier is 
however not essential for epicutaneous sensitization. It 
has been shown that high molecular weight antigens can 
be taken up by dendritic cells, which are present in hair 
follicles, which on turn can either initiate a sensitization 
or repression of immunological responses [13, 21]. Dur-
ing a sensitization period, different immunological pro-
cesses may lead to the full expression of allergy.
To summarize, susceptibility factors among different 
types of allergies other than CMA are well investigated. 
It is known that CMA is an ultimate complex disease 
involving different immunological pathways and differ-
ent environmental factors. Here we aim to discover new 
insight in the genetic susceptibility of CMA by means 
of: (1) Genetic association of six allergy associated com-
mon and high effect genetic variants identified by GWAS 
and (2) genetic association of rare but high effect genetic 
mutations in the filaggrin gene.
Methods
Dutch EuroPrevall Birth Cohort Study
In this study only children participating in the Dutch 
EuroPrevall Birth Cohort Study were investigated. The 
EuroPrevall study has been described in detail previously 
[3, 4, 22, 23]. In summary, children were included around 
birth and standardized measurements were performed 
by questionnaires. All children with symptoms suggestive 
of CMA underwent, among others a double blind pla-
cebo controlled food challenge (DBPCFC). Age-matched 
healthy control children were selected from the entire 
Dutch cohort. In both symptomatic and control children 
measurements where repeated annually. Controls had 
no symptoms suggestive of any food allergy nor suffered 
from atopic dermatitis. In all children undergoing blood 
drawing an attempt was made to obtain one full blood 
sample (EDTA KE 2.6 ml Monovette, Sarstedt BV, Etten-
Leur, Netherlands) for DNA-isolation too. The Medical 
Ethics Committee of the Academic Medical Hospital 
(METC 06/005) approved the Dutch EuroPrevall Birth 
Cohort Study. Written informed consent, for both the 
study and genetic sampling, was obtained from both par-
ents of each child, unless only one of them had parental 
rights.
CMA diagnosis
DBPCFC is the gold standard for diagnosing CMA and 
the challenge of choice according to the study protocol 
[22–24]. All children suspected of CMA were challenged 
according the international gold standard. The DBPCFC 
procedure was described in detail previously [3]. DBP-
CFC was repeated annually, in children with CMA, until 
the child was tolerant for CMP [3, 22]. Tolerance was 
defined as previously a positive DBPCFC for CMA, but at 
DNA-sampling a negative DBPCFC and/or eating CMP 
without experiencing symptoms.
Samples selected for genetic analysis
DNA samples of 20 children with proven CMA were 
selected, based on the longest possible time between the 
age of DNA-sampling and the age of CMP-tolerance. 
Since DNA is generally assumed to be stable throughout 
life we state that former CMA patients and active CMA 
patients represent both CMA cases. Also ten samples of 
children with proven CMA who developed CMP toler-
ance during the course of the study were selected, called 
former CMA children. Together these 30 samples are 
called the CMA-group. Control samples (N = 23), were 
selected from the group of control children and matched 
on age at DNA-sampling.
Patient characteristics were analysed with t test 
(Mann–Whitney U test when data was not normally 
distributed) for continuous parameters. Chi square test 
was used for categorical variables and Chi square test for 
trend for multiple categories categorical variables. All 
characteristics were analysed using SPSS version 20 (IBM 
SPSS Statistics for Windows, Armonk, NY).
Genetic association analysis
GWAS-studies reporting on SNPs associated with sensi-
tization and/or allergy were selected [25]. SNP Inclusion 
criteria were based on the minor allele frequency (MAF) 
of 20–50 % and an odds ratio (OR) >1.2 [26, 27]. Based on 
the literature and our prior stated selection criteria, six 
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SNPs were selected for evaluation. A description of the 
SNPs with regard nearby located genes is described in 
Table  1. Linkage disequilibrium (LD) was used to iden-
tify the most plausible involved gene, using LD plots per 
SNP on SNAP Broad institute with the following values: 
R2 = 0.8, distance limit = 500, CEU population [28]. Tar-
get reference sequences were downloaded using the data-
base ENSEMBL [29]. These reference sequences were 
subsequently submitted to the web tool Primer3 in order 
to obtain a primer set. Primers were M13 tail extended 
[30]. Primer sequences of all 6 SNPs are described in 
Additional file  1: Table S1. Final quality control of the 
primer set was performed using the web tool SNPCheck 
[31].
The FLG gene involves at least ten highly homolog 
repeat sequences. The primer sequences or primer design 
for detection of FLG mutations was based on the report 
of Sandilands et  al. [32]. In total we selected 13 FLG 
candidate mutations spread over repeats 1, 3, 4, 5, 6, 7, 
9 and 10 respectively (Table 2) [32]. Mutations reported 
only in the Chinese or Japanese population (3321delA 
and S2554X) were not included in this study. Since for 
most FLG primers specificity is based on not more than 
three repeat specific bases, the highest possible annealing 
temperature was used in the PCR in order to obtain the 
required regional specificity. All mutations were analysed 
using PCR, followed by Sanger sequencing. FLG Prim-
ers sequences are described in Additional file 1: Table S2. 
SNPs and FLG mutations were Sanger sequenced using 
standard protocols (BigDye Terminator® mix, Applied 
Biosystems) and analysed using an ABI3730® of Applied 
Biosystems.
Raw sequence data was analysed using CodonCode 
Aligner® and Alamut® software. Since all tested muta-
tions in the FLG gene result in an absent or defective 
protein, we constructed a cumulative variant score per 
patient. This cumulative score included a score of zero 
risk alleles versus one or more risk alleles present in 
exon 3 repeats of FLG. The CMA-group was compared 
to controls. In population based genetic studies the 
Hardy–Weinberg equilibrium (HWE) is a golden stand-
ard for quality control of the analysed genotypes. Devia-
tion of this equilibrium indicates genotyping errors or 
the presence of a certain genetic selection bias. Since we 
did analyze in this study a strongly selected sample of 
CMA patients, which obviously does not represent the 
general population, it would be inappropriate to apply 
the Hardy–Weinberg equilibrium as genotyping quality 
control in this study. All genetic statistical analyses were 
performed in SPSS (v20) using a Pearson’s Chi square 
test or Fisher’s exact test. P values <0.05 were considered 
significant.
Table 1 Candidate SNPs
Chr chromosome
* CEU genotype, NCBI database, HWP Hardy–Weinberg p value, NCBI database
a candidate SNP earlier reported by Ramasamy. A. 2011
b candidate SNP earlier reported by Bønnelykke K. 2013
SNP Chr Genotype* HWP Nearby gene(s): function
rs2155219a 11 G/G: 0,30 
G/T: 0,43
0.15 C11orf30: Regulator, represses transcription, possibly via its interaction with a multiprotein 
chromatin remodeling complex that modifies the chromatin. LRRC32: Associated with allergic 
rhinitis and rhinitis
rs17616434b 4 C/C: 0,06 
C/T: 0,31 
T/T: 0,62
0.371 TLR10: Toll Like Receptor 10. Pathogen activation, activation innate immunity. TLR1: Toll Like 
Receptor 1. Specifically recognizes diacylated and triacylated lipopeptide. TLR6: Toll Like Recep-
tor 6. This receptor functionally interacts with toll-like receptor 2. associated with an increased 
risk of asthma in some populations.  FAM114A1: May play a role in neuronal cell development
rs6586513a 1 A/A: 0,51 
A/C: 0,49
0.15 CROCC: Major structural component of the ciliary rootlet. Contributes to centrosome cohesion 
before mitosis. ATP13A2: ATPase Type 13A2. Transports inorganic cations and other substrates. 
SDHB: succinate dehydrogenase complex. Complex 2 of respiratory chain. MFAP2: Microfibril-
lar-associated protein. Major antigen of elastin-associated microfibrils
rs3860069a 4 A/A: 0,50 
A/C: 0,45 
C/C: 0,05
0.343 TLR6: Toll Like Receptor 6. This receptor functionally interacts with toll-like receptor 2. associated 
with an increased risk of asthma in some populations.  TLR10: Toll Like Receptor 10. Patho-
gen activation, activation innate immunity. TLR1: Toll Like Receptor 1. Specifically recognizes 
diacylated and triacylated lipopeptide. FAM114A1: May play a role in neuronal cell develop-
ment
rs6898653a 5 A/A: 0,59
A/G: 0,36 
G/G: 0,05
1 SEMA6A: expression in developing neuronal tissue. Is required for proper development of the 
thalamocortical projection
rs2069772a 4 A/A: 0,52 
A/G: 0,38 
G/G: 0,10
0.527 IL2: Interleukin 2. Secreted cytokine for proliferation of T and B lymphocytes. Produced by T 
cells. ADAD1: binds to RNA. Plays a role in spermatogenesis. KIAA1109: associated with celiac 
disease
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Results
Patient and control characteristics are shown in Table 3. 
Controls and children with CMA were well matched 
except for age at DNA-sampling. Children with CMA 
were significantly younger (P = 0.008) compared to con-
trols. Our CMA group consists of both IgE as well as 
non-IgE mediated CMA, with slightly more IgE positive 
children (specific IgE >0.35 kU/L, P = 0.044) in the CMA 
group compared to controls. Comparison of the former 
CMA group, showed no significant difference in age at 
DNA-sampling (P = 0.71) nor IgE status (P = 0.49).
Genetic contribution of common variants to CMA
For two SNPs we observed significant enrichment of risk 
genotypes in the CMA-group compared to controls, illus-
trated in Table  4. For rs17616434, located on chromo-
some 4; TLR10/1/6 and FAM114A1 locus, C/C risk alleles 
were absent in the control group while 9 CMA/former 
CMA subjects showed this genotype (P  =  0.002). The 
rs17616434 C/T and T/T genotypes were both enriched in 
the controls. For rs2069772 located on chromosome 4 as 
well, the T/T genotype was enriched in the CMA-group 
compared to the controls (80 vs. 46.7  % respectively), 
while the heterozygotes (C/T) and common genotype 
(C/C) was enriched in the controls (P  =  0.038). Analy-
sis based on the genotype frequencies within the CMA-
group vs. controls was insignificant associated (P > 0.05) 
for rs2155219 (LRRC32 locus), rs6586513 (CROCC/
ATP13A2/SDHB/MFAP2 locus), rs3860069 (TLR6/10/1 
and FAM114A1 locus) and rs6898653 (SEMA6A locus).
Genetic contribution of rare FLG mutations to CMA
The investigated FLG-mutations were covered by 9 
amplicons of which we successfully optimized PCR con-
ditions for 8 amplicons. The 4th amplicon, covering the 
R1474X mutation in FLG repeat 4, did not show con-
sistent results and was therefore excluded from analysis 
(data not shown). The latter mutation is extremely rare 
and was only reported in the Irish population [32].
Figure  1 illustrates the percentage of present 
risk alleles per group. According to the report of 
Table 2 Selected filaggrin mutations according Sandilands et al.
a Sandilands reported p. 3683. FLG filaggrin, g genomic position, c coding postion, ATG distance from transcription start site, bp basepair change(s), p. affected amino 
acid
b Ethnic group were mutations were first reported, adapted from Sandilands et al. EUR (European), AM (American.), IR (Irish), AUS (Austrian), NL (Dutch)
FLG mutation Amplicon Repeat g. (H19) c. ATG bp p. Ethnicityb
R501X FLG-1 1 152285861 1501 2072 C>T 501 EUR/AM
2282del4 FLG-2 1 152285080 2282 2853 del4 (CAGT-2286) 761/762 EUR/AM
3702delG FLG-3 3 152283660 3702 4273 delG 1234 IR
R1474X FLG-4 4 152282942 4420 4991 C>T 1474 IR
5360delG FLG-5 5 152282002 5360 5931 delG 1787 NL
6867delAG FLG-6 6 152280495 6867 7438 delAG (AG-2268) 2289/2290 AUS
E2422X FLG-7 7 152280098 7264 7835 G>T 2422 NL
7267delCA FLG-7 7 152280095 7267 7838 delCA (CA-7268) 2423 NL
R2447X FLG-7 7 152280023 7339 7910 C>G 2447 IR
S3247X FLG-8 9 152277622 9740 10311 C>A 3247 IR
11029delCA FLG-9 10 152276333 11029 11600 delCA (CA-11030) 3677 IR
11033del4 FLG-9 10 152276329 11033 11604 Del4(CAGT-11036) 3678/3679 NL
Q3683X FLG-9 10 152276312 11050 11050 C>T 3684a Ir
Table 3 Characteristics of Dutch allergy study population; 
cow’s milk allergy (CMA), former CMA and controls
CMA cow’s milk allergy, N number, CMP cow’s milk protein, SD standard 
deviation, NA not applicable, NS not significant, sIgE serum specific IgE
a age in months ANOVA
b Fisher’s exact test, 2-sided
CMA Control P
N (♀) 20 (8) 20 (10) NS
Age diagnosis CMA ± SDa 6.5 ± 2.5 NA NA
Age at Sampling ± SDa 11.8 ± 4.9 17.2 ± 7.1 0.008
N of children with CMP specific 
sIgE >0.35 kU/Lb
7 1 0.044
Mean CMP specific sIgE value ± SD 
(kU/L)
1.15 ± 3.6 0.16 ± 0.64 NS
Range IgE value (kU/L) 16.4 2.9 NA
Former CMA Control P
N (♀) 10 (0) 13 (0) NA
Age diagnosis CMA ± SDa 5.8 ± 2.2 NA NA
Age at Sampling ± SDa 18.0 ± 5.6 17.2 ± 4.3 NS
Age at Tolerance ± SDa 17.2 ± 3.9 NA NA
N sIgE >0.35 kU/Lb 0 0 NA
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Sandilands et  al. [32] some mutations were, so far, 
only observed in European and/or Dutch populations 
annotated as dashed bars in this figure. One sample, 
homozygote for the 2282del4 mutation involved a 
CMA patient. Geographic origin/ethnicity are known 
confounders in genetic surveys. Therefore, we evalu-
ated the ethnic distribution (Fig.  2) and observed no 
difference between the two groups. All FLG muta-
tions are rare, and in combination with a relative small 
sample, this implies extremely low statistical power. 
In order to diminish this power problem we counted 
per sample the number of present mutations yielding 
a cumulative FLG risk allele score. Samples who car-
ried 1 or more risk alleles were annotated as 1. Figure 3 
illustrates the scores in the CMA-group and controls. 
Although insignificant (Chi square test), more risk 
alleles carriers were present in the CMA-group com-
pared to controls.
Table 4 Comparison of SNPs between cow’s milk allergy (CMA), former CMA and controls
CMA cow’s milk allergy
SNP Group Genotype details P value
rs2155219 GG GT TT Total 0.548
CMA + former CMA 6 (24 %) 11 (44 %) 8 (32 %) 25 (100 %)
Control 7 (23.3 %) 17 (56.7 %) 6 (20 %) 30 (100 %)
rs17616434 CC CT TT Total 0.002
CMA + former CMA 9 (36 %) 5 (20 %) 11 (44 %) 25 (100 %)
Control 0 (0 %) 10 (33.3 %) 20 (66.7 %) 30 (100 %)
rs6586513 AC AA Total 0.456
CMA + former CMA 12 (48 %) 13 (52 %) 25 (100 %)
Control 11 (37.9 %) 18 (62.1 %) 29 (100 %)
rs3860069 CC AC AA Total 0.336
CMA + former CMA 4 (16 %) 8 (32 %) 13 (52 %) 25 (100 %)
Control 2 (6.7 %) 7 (23.3 %) 21 (70 %) 30 (100 %)
rs6898653 GG AG AA Total 0.951
CMA + former CMA 1 (4 %) 13 (52 %) 11 (44 %) 25 (100 %)
Control 1 (3.4 %) 14 (48.3 %) 14 (48.3 %) 29 (100 %)
rs2069772 CC CT TT Total 0.038
CMA + former CMA 1 (4 %) 4 (16 %) 20 (80 %) 25 (100 %)
Control 2 (6.7 %) 14 (46.7 %) 14 (46.7 %) 30 (100 %)
Fig. 1 Enrichment analysis of filaggrin risk alleles in cow’s milk allergy patients vs. controls. Percent present risk alleles: total number of alleles/num-
ber of risk alleles per group [cow’s milk allergy (CMA) patients, former CMA patients and controls]. Dutch/EUR pop column indicates for every FLG 
mutation the discovery population according Sandilands et al. only and does not represent an actual percentage
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Discussion
In this study we observed association of two earlier 
reported non-CMA allergies and/or allergy sensitization 
associated SNPs with CMA. Although insignificant, we 
observed more FLG mutations in the CMA-group com-
pared to controls which suggest that a role of the FLG-
gene in CMA cannot be excluded. Since our candidates 
were earlier reported to be associated with other types 
of late(r) onset allergic diseases, our data suggest not 
only that rs17616434, rs2069772 and FLG mutations are 
involved in CMA, but also suggest that these genetic var-
iations might contribute to the so-called “allergic march”.
Genetic analysis
We analysed six SNPs which have been described previ-
ously in relation to allergic diseases [26, 27]. Out of these 
six, two SNPs showed significantly different genotypic dis-
tribution between CMA and controls. First, rs17616434 
(P = 0.002) was associated with CMA and is located near 
a cluster of toll like receptor (TLR1, 6, 10) genes, which 
has earlier been associated with allergic disease [33]. Sec-
ondly, rs2069772 (P = 0.038), was earlier described to be 
associated with allergic rhinitis, and is located near the 
IL2 and KIAA1109 genes [27]. IL2 is known to be involved 
in cytokine secretion that stimulates proliferation of B 
and T -cells. The other gene, KIAA1109, is known to be 
involved in celiac disease, a disease characterized by a 
strong immunological response to food proteins (glu-
ten), found in wheat, rye and barley [34]. Moreover, the 
KIAA1109/Tenr/IL2/IL21 locus was also earlier associ-
ated with another immunological disorder, namely rheu-
matoid arthritis [35]. Therefore, both IL2 and KIAA1109 
are good candidates to be involved in CMA. Earlier 
reports involving allergic diseases have shown that a 
defective FLG-gene was involved, albeit the prevalence 
of these mutations is ethnicity specific [32]. In our cohort 
we constructed a cumulative score of FLG-mutations. 
Although, the absolute number of mutations was higher 
in the CMA-group this difference was not statistical sig-
nificant. The presence of ethnic specific mutations in our 
sample of mainly Dutch children was in concordance with 
the report of Sandilands et al., with exception of S3247X 
mutation, which was reported only in the Irish popula-
tion [32]. Since FLG mutations are rare and our study 
sample is small we cannot state that FLG is not involved 
in CMA. To our knowledge, FLG has not been studied in 
CMA before. Therefore, studies involving a larger sample 
size are necessary to conclusively rule out or rule in the 
involvement of FLG in CMA.
Allergic march
The allergic march hypothesize that children who suf-
fered from food allergy or atopic dermatitis in early child-
hood have an increased risk of developing other allergic 
diseases, e.g. asthma and allergic rhinitis, in later in life. 
However, evidence for the existence of the allergic march 
is still very limited [6–12]. Recent reports describe path-
ways involved in allergic diseases and implied common 
genetic variation behind these affected pathways, among 
others, defects involving the skin barrier. The filaggrin 
protein is involved in maintaining a healthy skin bar-
rier [18, 36]. Although in our study rare FLG mutations 
were not significantly enriched in CMA patients, we did 
Fig. 2 Ethnicity distribution among cow’s milk allergy (CMA), former 
CMA patients and controls Caucasian: both parents are of Caucasian 
background. Mixed: one parent is of Caucasian and one parent of 
non-Caucasian background. Non-Caucasian: both parents are of non-
Caucasian background
Fig. 3 Enrichment analysis of filaggrin risk alleles in cow’s milk allergy 
patients vs. controls Percentage ≥1 risk alleles represents a cumula-
tive score of all filaggrin (FLG) mutations within cow’s milk allergy 
(CMA) + former CMA and control groups. WT Wild type
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observe more FLG mutations in our CMA group. The 
function of regulatory T-cells and the Th2 responses have 
been previously reported in relation to allergic diseases as 
well. These pathways have been associated with several 
other allergic diseases, which might favour the allergic 
march hypothesis, since the onset of these different types 
of allergies seem to manifest at specific ages [18, 36]. In 
our small sample study, we found a significant associated 
locus located close to the IL2 gene which is involved in the 
Th2 response. Both our observations on FLG mutations 
and the IL2 locus favour the allergic march hypothesis but 
have to be confirmed in a prospective study design.
Strength and weaknesses of the study
The main strength of the studied samples is that CMA is 
diagnosed according to the current available, internation-
ally recommended, gold standard [24]. Furthermore, clinical 
data are well documented due to the setup of the study with 
regular questionnaires [22]. Unfortunately, it was not possi-
ble to obtain DNA-samples in all children. Furthermore, the 
amount of blood drawing for research purposes in infants is 
in the Netherlands limited to 2.5 ml. These are both limiting 
the sample size of this study. This resulted in missing values 
for statistical analysis, however there were no significant 
differences in distribution between valid and missing cases 
between CMA-infants and controls (data not shown). Since 
this is only a very small sample size study in a very heteroge-
neous disease, further studies in larger cohorts are necessary. 
Obviously, many more genetic and environmental factors 
are involved in the development of CMA. With respect to an 
epidemiological approach unravelling mechanisms involved 
in CMA, large cohorts are essential. On the other hand, 
using well characterized small cohorts or even single cases 
might be essential to elucidate distinct mechanisms, that 
underlie at the basis of the complex character of CMA.
Conclusion
Current studies indicates that genetic variation of TLR6 
and IL2, which were earlier reported to be associated 
with non-CMA allergies and/or allergy sensitization, 
contribute to the expression of CMA in young children. 
In addition, this favours the “allergic march” hypothesis. 
Furthermore, we cannot exclude a possible role for FLG-
mutations being involved in CMA or the sensitization 
process prior to the establishment of CMA. Follow-up 
studies are necessary before definite conclusions about 
a link between early onset CMA and expression of later 
onset other allergic diseases can be drawn.
Additional file
Additional file 1. Primer sequences. a Primer sequences candidate SNPs, 
b Primer sequences candidate Filaggrin (FLG) mutations.
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